Computational Modeling of Bispecific Antibodies for CD30+ Hodgkin Lymphoma & Anaplastic Large Cell Lymphoma

RITHVIK VENISETTY[1,2] AND GAURAV SHARMA[2]

[1]Grand Blanc High School, Grand Blanc, MI
[2]Eigen Sciences, NC, Apex

Published October, 2025

Lymphoma remains one of the most prevalent forms of cancer, with over 80,000 cases diagnosed annually in the U.S. alone. The CD30 receptor, overexpressed in lymphoma cells, is essential for cancer cell proliferation and survival, making it a critical therapeutic target. The CD3ε receptor subunit is found on immunocompetent lymphocytes and promotes activity in response to specific antigens. Bispecific antibodies (bsAbs) can bind to two antigens simultaneously, facilitating immune cell-mediated cytotoxicity. This research aims to identify Fab regions in silico that can bind to CD3e and CD30 receptors while also providing a model bsAb discovery pipeline. To formally investigate how scientists may consider using these technologies for bsAb development, this study hypothesizes that using computational analysis of various Fab fragments and the CD30 and CD3ε receptors will aid in recognizing antibodies that bind to CD8+ cells and lymphoma cells, respectively, resulting in the identification of potential treatments. The receptor and antibody structures were obtained from the AlphaFold 3 webserver and Protein Data Bank (PDB), respectively. Molecular docking was performed using HDOCK to model receptor-antibody interactions, and resulting complexes were evaluated using HADDOCK PRODIGY webserver, a computational program to compute binding energy. Key criteria of Fab fragment selection included binding energy, hydrogen bond count, and visual inspection of docking conformations. Notably, Fab fragment 1IQW demonstrated the highest binding affinity (-25.6 kcal/mol) and the highest hydrogen bond count of 28 for the CD3ε receptor. 1A5F had the highest binding affinity (-23.0 kcal/mol), though a low hydrogen bond count of 7, for the CD30 receptor. This research developed a model pathway for producing effective bispecific antibodies targeting the CD30 and CD3ε receptor chains while demonstrating the potential of computational techniques for bsAb development.

1. INTRODUCTION

Lymphoma, encompassing both Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL), made up approximately 0.4% and 4%, respectively, of all new cancer cases in 2024, resulting in a combined 3.4% of cancer-related deaths [1]. In lymphoma, the lymphatic system's white blood cells, known as lymphocytes, divide uncontrollably, producing cancerous cells that crowd out healthy tissue. NHL often originates in lymph nodes of the upper body, including in the neck, under the arms, or in the abdomen, while HL can originate anywhere in the body. Symptoms of this disorder include swollen lymph nodes, fatigue, fever, itchy skin, and more [2]. Currently, there are many treatments for lymphoma, including chemotherapy, radiation therapy, and immunotherapy [3,4]. Nevertheless, lymphoma has the inherent ability to spread quickly as it involves blood cells that flow throughout the body. Due to its often-non-specific symptoms, identifying the most optimal treatment plan for patients can be extremely difficult [5].

Immunotherapies use the body's natural immune responses and help them function more effectively against certain diseases [6]. Clinical studies have demonstrated their success through various approaches, including immune checkpoint inhibitors, which treat cancers by blocking proteins that prevent T cells from killing cancer cells [7]. The specific nature of immunotherapies will continue to motivate their success as they grow over the following years. Additionally, with movements such as the Precision Medicine Initiative (PMI), treatments that consider everyone's disease phenotype will grow in demand. Immunotherapies that can be slightly modulated per the disease mechanisms unique to individual patients or patient subgroups will provide

safer and more effective procedures [8].

Bispecific antibodies (bsAbs), a leading advancement in immunotherapy, represent a potent class of therapeutic molecules recognized for their potential as an effective solution to various cancers and autoimmune diseases. bsAbs are engineered molecules that rely on specific physical arrangements to enhance the immune system's efficiency [9]. The dual-targeting nature of each molecule allows for specificity in targets while providing the simple advantage of only having to engineer a single protein. bsAbs have shown efficacy in treating various diseases, including rheumatoid arthritis, hemophilia, multiple myeloma, and more. bsAbs have also been used in cancer treatment, including lymphoma [5,10,11]. Due to their fast-acting applications in cancer treatment and their modularity, they may appear in many more applications soon.

A commonly targeted receptor for various subtypes of lymphoma is CD30/TNFRSF8. CD30 is a tumor necrosis factor receptor (TNFR) that functions as a communications hub, regulating pathways involved in cell survival, cell differentiation, and apoptosis. CD30 ligand (CD30L) triggers signaling pathways that can promote the survival of both healthy and cancerous lymphoma cells [12]. The receptor is commonly overexpressed in HL and some NHLs, including the rare and aggressive Anaplastic Large Cell lymphoma (ALCL), characterized by large, non-functioning lymphoma cells. As a cell surface receptor, it has great therapeutic potential, making it a crucial target for various drugs, including monoclonal antibodies (mAbs). [1314]. Although this receptor is found on many species of CD4+ and CD8+ lymphocytes, significant overexpression of CD30 in cancer cells helps to reduce unwanted binding of drugs to healthy cells.

CD3 epsilon (CD3ε) is a different yet equally important complex involved in many signal-transduction pathways in T-cells. It is a part of CD3, a complex of proteins that plays a critical role in T-cell signaling and forms a heterodimeric complex with the T-cell receptor (TCR). Through CD3ε's activation, a signaling cascade results in T-cell proliferation and TCR engagement with MHC I, helping the immune system respond to diseased cells [15]. Moreover, it is clearly located on the surface of CD8+ (cytotoxic T-cells) and is considered the most exposed subunit of the CD3 protein, making it a druggable site that has been targeted by many mAbs [16]. This receptor is also underexpressed in HL, allowing mAbs to target primarily healthy cells. Anticancer treatments have the potential to bind to the CD3ε receptor to help T-cells recognize the cancer cell and become fully active [12].

Protein binding assays, such as phage display and ELISA, are commonly used to develop molecules like bsAbs. Phage display involves using bacteriophages to present peptides on their surfaces, allowing researchers to identify binders. ELISA (enzyme-linked immunosorbent assay) is a technique that uses antibodies and color changes to detect and quantify specific proteins [17]. Although effective, these methods can be time-consuming for contemporary laboratories and pharma organizations. Thus, molecular docking has been popularized as an effective way to test drug molecules before production [18]. Molecular docking is a technique used to model interactions between a small molecule, most commonly a drug or a ligand, and a larger molecule, like a receptor or enzyme. It involves predicting how a drug wants to bind to the target protein's active or binding site to emulate the processes that may occur in natural environments. By doing this, the strength and stability of the interaction (binding affinity) can be estimated to understand how effectively the drug will attach [19]. Generative algorithms called search algorithms aim to find the possible orientations of each molecule while scoring functions evaluate the binding potential and predict the strength of interactions. This method is extensively used in drug discovery and development, and it enables researchers to go through a large set of compounds to identify possible candidates for drugs without doing expensive lab testing. It is now a crucial tool for computational biology and medicinal chemistry.

Historically, chemotherapy, radiation therapy, and immunotherapy have been used to treat lymphomas. Many bsAb medications, including Mosunetuzumab and Epcoritamab, have already been developed and currently show promise in treating relapsing lymphoma [20]. In a phase 1/2a trial, a bispecific antibody binding to the CD3 receptor of the T-cell and the CD30 receptor present on the Hodgkin and Non-Hodgkin cells was created to stimulate cytotoxicity, as seen in **Figure1** [21]. Although this provides evidence to use this pair of receptors as targets, finding Fab fragments to form the epitopes of bsAb molecules can be challenging. Their selection can be limited to in vitro identification, with inefficiency in testing being a crucial issue in production. Developing new therapeutic molecules, particularly bsAbs, is a complex and resource intensive process. However, the integration of computational and artificial intelligence (AI) technologies into the production of bispecific antibodies remains limited, leaving opportunities for innovation.

Recent breakthroughs in computational biology have revolutionized our ability to predict complex structures, playing pivotal roles in scientific discovery. As these tools continue to evolve, they show evidence of accelerating the development of effective treatments for complex diseases. It is unclear whether research laboratories working on bsAb production are using contemporary AI or computational models to enhance output. To formally investigate how scientists may consider using these technologies for bsAb development, this study hypothesizes that using computational analysis of various Fab fragments and the CD30 and CD3ε receptors will aid in recognizing antibodies that bind to CD8+ cells and lymphoma cells, respectively, resulting in the identification of potential treatments. This study focuses on cancer types that have shown significant overexpression of the CD30 receptors to use for in silico modeling to design bispecific antibodies potentially targeting HL and ALCL cells.

2. RESULTS

In this work, computational analysis and prediction of antibody docking to produce bsAbs in lymphoma treatment has been performed.

Binding site prediction: To understand the surface properties of the CD3ε and CD30 receptors, protein binding site was predicted. After acquiring the Protein Data Bank (PDB) files for both receptors, their binding sites were located using ScanNet, an AI binding affinity software, which are displayed in **Figure 2a and 2c**. Using ChimeraX-1.8, electrostatic surface potential was also visualized as seen in **Figure 2b and 2d**. In the receptor molecules CD3ε and CD30, different regions are located above and below portions of the cellular membrane. Referring to **Figure 2**, the divisions of receptor molecules can be easily recognized. Within the cell, the endodomain, the receptors form curved and convoluted structures due to peptide interactions and to enhance signal transduction pathways. Within the trans domain, or the cell membrane, the receptors maintain a neutral charge to reduce repulsion from the fatty acid chains of the phospholipids. Finally, the outermost region, called the ectodomain, contains the area with the highest binding affinity. The antibodies bind in this region, as indicated by the difference



Fig. 1. Schematic of Bispecific Antibody: The CD3ε receptor is present on the surface of the cytotoxic T-cell, while the CD30 receptor is located on the cancer cell's surface. A bispecific antibody interacts with both receptors and physically links the T-cell and the cancer cell, forming an immunological synapse between them.

in coloration; thus, the search for Fab fragments was generally constrained to these areas when possible.

Visual identification of optimal binding locations: Our analysis compiled a list of binding scenarios in a fixed set of 10 Fab fragments, with most receptors forming a binding complex in the extracellular matrix of the cells. The docking software provided the 10 top models with individual docking energy scores and ligand RMSD values for accuracy and structural integrity. The most visually capable docking structure was chosen out of these models for each Fab fragment, as seen in **Figures 3 and 4,** by assuring they were in accordance with the binding sites identified during binding site prediction. These models were then collected and utilized for the next tests.

Hydrogen Bond Count and Binding Affinity: Unlike the previous visual or descriptive analysis, numerical data regarding binding energy and the amount of hydrogen bonds was calculated with much more quantitative standards. The analysis determined that the Fab fragment 1IQW demonstrated the highest binding affinity (-25.6 kcal/mol) and the highest hydrogen bond count (28) for the CD3ε receptor. 1A5F was determined to have the most optimal binding affinity (-23.0 kcal/mol), though with a low hydrogen bond count (7), for the CD30 receptor. The findings suggest that, with this specific data set and methodology, a bispecific antibody containing the 1IQW and the 1A5F fragments would be most effective in treating certain lymphoma groups with overexpressed CD30 receptors. The results can be seen in Table 1

Antibody Design: The previous analyses led to the development of a bispecific antibody structure as seen in **Figure 5,** combining the fragments 1A5F and 1IQW with a previously known antibody. This structure may be used as a baseline to further examine efficacy and immunogenicity, or the potential to cause unwanted immune reactions, in vitro.

Novel Epitope Modeling. DeepAB, a deep-learning tool for structure prediction, was used to determine the structure of various epitopes that may be found on antibody chain structures. The binding complexes were obtained using the same methods from using the Fab regions from Protein Data Bank, allowing for the calculation of binding energy and hydrogen bond counts. As seen in **Table 2,** Fv4 had the greatest binding energy for CD3ε (-19.6 kcal/mol) with a hydrogen bond count of 6. Fv1 had the greatest binding energy for CD30 (-18.3 kcal/mol) with a hydrogen bond count of 8.

3. MATERIALS AND METHODS

Overview: To determine the most optimal Fab regions in developing a bsAb for the CD30 and CD3ε receptors, the Fab struc-



Fig. 2. Surface Properties of Receptors.(a) The binding site of the CD3*ε* receptor is located in the ectodomain or extracellular matrix; (b) The electrostatic surface potential of the CD3*ε* receptor protein is mainly negative in the outer region; (c) The binding region of the CD30 receptor is primarily located in the ectodomain; and (d) The electrostatic surface potential of the CD30 receptor protein is visualized.



Fig. 3. Docked Structures of CD3ε-Antibody Interactions: Each receptor input was configured to the 10 top models, out of which the most visually optimal were selected.



Fig. 4. Docked Structures of CD30-Antibody Interactions. Each receptor input was configured to the 10 top models, out of which the most visually optimal were selected.

Table 1. Receptor-Antibody Binding Energy and Hydrogen Bonds: This data was used to determine the most optimal antibody-receptor complexes for CD30 and CD3*ε*

Ligand	Binding Energy (CD3ε) (kcal/mol)	Binding Energy (CD30) (kcal/mol)	Hydrogen Bonds (CD3ε / CD30)
1A5F	-23.0	-23.0	20 / 7
1B4J	-24.4	-21.0	12 / 5
1F8T	-24.7	-21.2	11 / 18
1Fl5	-23.5	-21.3	10 / 16
1iL1	-22.0	-14.1	5 / 23
1IQW	-25.6	-22.9	28 / 17
1NLB	-23.4	-19.9	22 / 20
2HRP	-16.9	-21.9	15 / 40
2UYL	-12.5	-21.6	7 / 23
4A6Y	-11.1	-10.8	5 / 13

Table 2. Fv-Antibody Binding Energy and Hydrogen Bonds: This data was used to determine the most optimal Fv-receptor complex from the epitopes acquired from DeepAB.

Ligand	Binding Energy (CD3ε) (kcal/mol)	Binding Energy (CD30) (kcal/mol)	Hydrogen Bonds (CD3ε / CD30)
Fv1	**-19.0**	**-18.3**	**16 / 8**
Fv2	**-18.7**	**-16.3**	**12 / 8**
Fv3	**-15.1**	**-15.9**	**10 / 18**
Fv4	**-19.6**	**-17.9**	**9 / 9**
Fv5	**-15.7**	**-15.2**	**5 / 9**
Fv6	**-15.0**	**-17.9**	**6 / 8**
Fv7	**-14.8**	**-14.3**	**8/ 8**
Fv8	**-15.9**	**-14.8**	**5/ 11**
Fv9	**-14.9**	**-17.2**	**4 / 4**
Fv10	**-15.4**	**-15.6**	**7 / 13**



Fig. 5. Engineered Antibody Structure. The selected Fab regions were chosen to develop a hypothetical model of an engineered bsAb that consists of clearly defined chains. The final antibody incorporates the most optimal Fab fragments, 1A5F and 1IQW.

tures were obtained and tested for their structural alignment with each receptor protein. Complexes containing both protein chains were analyzed for their binding ability in terms of hydrogen bond count and binding energy, and the resulting data was compared to determine the most optimal pair of Fab regions. The overall procedure can be clearly visualized below in **Figure 6.**

Receptor Structure Modeling. Uniprot [22], one of the largest databases of protein sequences and functional information, provided the receptor chains for this study. As a comprehensive tool, finding suitable structural representations of the CD30 and CD3ε receptor chains was streamlined. Through the UniProtKB database, CD3ε and CD30 protein sequences (Homo Sapiens) were exported for analysis through the AlphaFold 3 server. AlphaFold3 [23] is an artificial intelligence (AI) that uses machine learning to predict the 3D structure of proteins from their amino acid sequences and intra-protein interactions. It uses a complex deep-learning system, as displayed in **Figure 8,** that takes previously defined structures from the AlphaFold database and finds similar sequences that are used as a basis for predictive modeling. Using it allowed the protein structure confidence to be analyzed and assess if the structures were optimal for this study. Analysis returned CD3ε with a predicted template modeling (pTM) score of 0.47 and CD30 with a pTM of 0.27, both under the optimal range for high confidence and moderate confidence (pTM > 0.5). Nevertheless, it was determined that because of the large percentage of very high per-residue confidence scores (pLDDTs) for the anticipated binding regions within the proteins (pLDDT>90), which are confidence scores for amino acid (residue) location, and the large amounts of loop regions and flexible tails in both receptors that contributed to the low pTM, our analysis would be unaffected. From AlphaFold 3, the protein structures were opened through ChimeraX-1.8. [24] As a user-friendly modeling tool, importing PDB files allows the software to visually represent the properties of proteins.

Antibody selection: The following criteria were used to determine the most appropriate Fab candidates: Visual analysis, binding energy, and hydrogen bonding. The most optimal binding sites were visualized using the ScanNet software [25], a deep learning (DL) model that highlights features from 3D structures. The regions in blue, as seen for the CD3ε and CD30 receptors in **Figure 2a and c**, respectively, represent the regions of the receptors with the highest binding affinity. The binding site is shown in the black box. The optimal binding scenarios could be more accurately represented using this visual characteristic. Additionally, the ChimeraX-1.8 software assisted in the visual analysis. Through this software, electrostatic representations of the molecules called electrostatic surface potentials (ESP) were formed, with red indicating negative and blue indicating positive as shown in Figu**re 2b and 2d**.

Antibody Structure Download: Structures were collected via Protein Data Bank [26], an archive of 3D structure data for biological molecules, to complete a set of Fab fragments usable for analysis. By providing 3D structures for these molecules, they could easily be analyzed through the computational analysis tools used in the study. For the list, the fragments included the following: PDB ID = 1A5F, 1B4J, 1F8T, 1FL5, 1IL1, 1IQW, 1NLB, 2HRP, 2UY1, and 4A6Y. These Fab fragments were selected based on their structures and ability to remain exclusive to the CD3ε and CD30 receptors. Additionally, many of the structures were acquired from Mus Musculus instead of Homo Sapiens due to their higher data availability and overall homology with human proteins.

Receptor-Antibody Molecular Docking: Using computational tools, the HDOCK [27] modeling software was used to find the optimal binding scenario and ligand structure. In doing so, the software provided the top 10 results and additional RMSD data. Finding receptors that bind to areas of high affinity, prefer-



Fig. 6. Overview of Research Methodology. This diagram illustrates the step-by-step approach used in the study, highlighting key steps involved in in silico bispecific antibody development. The flowchart visually represents the sequence of methods, including using docking and bond interaction analysis to reach an optimal Fab fragment pair. Each step is designed to optimize the accuracy and efficiency of data collection and analysis in research.

ably in the ectodomain, resulted in selecting 10 specific receptor configurations determined to be "optimal" through the previously outlined visual criteria. With this, the optimal binding and structural scenarios for antibodies were selected, as can be seen in **Figures 3 and 4**. Next, more specific data regarding binding affinity and hydrogen bond count were to be determined.

Receptor-Antibody Molecular Docking Analysis: The receptor-antibody complex structures were downloaded and analyzed after the molecular docking simulations. The binding energies of the antibodies with the CD30 and CD3ε receptors molecules, respectively, were calculated to create a binding affinity ranking. Binding energy measures the overall strength of the interaction between the ligand and target molecules. Higher binding energy indicates a more vital, stable interaction crucial for therapeutic efficacy. It also implies the time that antibodies will bind with the receptor, increasing the probability that the bsAbs will interact with both types of cells. Using the HADDOCK Prodigy Web Server [28], another computational analysis software, the PDB files of the antibody-receptor complexes recovered from the HDOCK software were inputted with minor adjustments to the file script. By analyzing this, a value for binding energy (kcal/mol) was received for each complex. This data was the key determinant in our conclusion regarding the most effective antibody for producing a bsAb. The hydrogen bond count between the ligand and receptors was also calculated using in-house Python-based software. The Python code used to calculate the hydrogen bond count between each receptor protein and antibody chains can be found on GitHub [29]. Only the strongest bond interactions between atoms of nitrogen or oxygen were calculated with a maximum distance of 2.7 Å.

Preliminary results from selection criteria: After organizing this data, as seen below in Table 1, the criteria necessary for completion had been determined and analysis could finally begin. Due to the higher ranking of binding energy over hydrogen bond count, the most optimal antibodies were determined. The 1IQW fragment demonstrated the highest binding affinity (-25.6 kcal/mol) and the highest hydrogen bond count (28) for the CD3ε receptor. 1A5F had the most optimal binding affinity (-23.0 kcal/mol), though with a low hydrogen bond count (7), for the CD30 receptor. Despite the low hydrogen bond count compared to other antibody-receptor complexes, the predetermined hierarchy of factors led to the conclusion of 1A5F being the most optimal for CD3ε. Thus, the combination of the 1A5F and 1IQW Fab fragments provided the best estimated scenario for binding.

Antibody Generation: IA5F and 1IQW were combined with the Ig structure of PDB ID 1IGT to generate a complete antibody structure that may be tested for binding in vitro. As seen above in **Figure 6,** the protein sequences were edited to form two light chains and two heavy chains, effectively combining the Fab fragments with the antibody. Structural analysis through ChimeraX-1.8 additionally demonstrated that few to no hydrogen bonds existed within the hinge joint of the engineered antibody. Due to bsAb's purpose of binding two targets simultaneously, this lack of hydrogen bonds in this region contributes to the high flexibility of the molecule, increasing the probability that it would be viable in-vitro. This structure may be subject to additional computational and laboratory testing to identify any shortcomings as an effective lymphoma treatment.

Novel Antibody Structure Prediction: To more effectively generate new Fab region sequences for analysis, DeepAB was used for predictive modeling. DeepAB is a deep-learning software that is considered more optimal than AlphaFold 3 for antibody generation due to it being optimized in predicting the

complementarity-determining regions (CDRs) and epitopes of antibodies [30]. These regions are crucial for antigen recognition and are directly involved in binding, presenting it as the more optimal tool for this procedure. PDB files for the variable domain (Fv) composed of portions from each chain, variable heavy (VH), and variable light (VL). The software outputted a predicted variable region for each pair of VH and VL chains, which were then used along with HDOCK and HADDOCK Prodigy Web Server to determine the best epitopes, as seen in **Table 2.** Fv4 had the highest binding energy for CD3e (-19.6 kcal/mol) with 9 hydrogen bonds, and Fv1 had the highest binding energy for CD30 (-18.3 kcal/mol) with 8 hydrogen bonds. Analysis of these epitopes and variable chains shows how scientists may create novel Fab fragments for bsAbs, enhancing output using AI modeling software.

4. DISCUSSION

This study utilized computational analysis and DL to investigate their potential in developing bsAbs for lymphoma. Critical structural and functional parameters influencing binding specificity and stability were compared by simulating interactions between receptors commonly found on lymphoma and CD8+ cells. Our findings align with previous research regarding CD3ε and CD30 as potential target receptors for immunotherapies [21]. Additionally, the computational approach demonstrates the utility of in silico methods in accelerating antibody design and reducing reliance on resource-intensive laboratory research.

Comparison with Previous Studies: Historically, bsAb development has been slow and resource-draining, limiting its availability for various diseases and cancer species. Many manufacturing techniques have been used for bsAb synthesis and testing, each resulting in unique structural properties. However, many bsAb development trials have begun with typical in vitro pathways that primarily utilize dual-target binding assays, phage display, or ELISA assays to identify potential candidates for bsAb technology [31]. Though these methods produce results, they are often based on a trial-and-error process, have shown significant bias, and do not consistently provide substantial results [32]. Pairing optimization and screening for affinity testing in vitro, although necessary, may not be the optimal first step, especially when dealing with randomized sets of antibody chains. Many previous studies focus on proteins that have already had significant analyses of their properties, so a computational and AI based approach would be able to determine characteristics including binding energy, epitope location, antigen size, and extracellular interactions that are difficult to determine otherwise.

More recently, high throughput/single cell screening have been developed to more efficiently use samples to engineer bsAb variants. Analyses sorted various clones generated by the system based on specific variables, thus showing improvement in bsAb design and functionality [32]. Still, the integration of DL has been slow when compared to other examples of antibody development. Of course, there have been a small handful of notable applications of computational and AI in this field. For example, a research study utilized novel AI computational frameworks for selecting target receptor combinations for bispecific antibodies when focusing on research and development. Though this study offers significant insight into cancer treatment using bsAbs, this model relies heavily on data from clinically approved bispecific antibodies and does not consider different Fab regions. Additionally, without a focus on developing antibody structures, it primarily aids in receptor identification [33]. New services claim to use AI modeling to develop bispecific and multispecific molecules, yet their methods are not publicly disclosed. A clear lack of literature referencing DL software may be indicative of the need for a more efficient pipeline for discovery, which this study addresses.

Applications and Limitations: Through this analysis, it can be determined that machine learning tools and computational studies can be used in the production of bsAbs not only for lymphoma but also for other cancers and diseases. bsAbs for lymphoma are produced in the lab at a large scale using the optimal antibody combinations. Once injected into the bloodstream, these structures can travel throughout the body, binding to lymphoma cells and CD8+ T-cells to help accelerate the immune response. Although this research may permit the extension of computational analysis in bsAb development, it can only be a preliminary milestone in developing new antibodies. Clinical testing and laboratory analysis should be performed to validate antibody binding further, and it may be of interest to create a model that combines many of these tools used to form a development pipeline.

Additionally, as this study only introduces a pathway into AI modeling in bsAb analysis, it comes short on important factors that are considered contemporary challenges in bsAb development. Risk factors and response prediction are still uncertain in treatment production and administration, and mechanisms or resistance are still present that may prevent bsAbs from achieving greater efficiency. Intrinsic mechanisms, including immune-evasive gene expression, may neutralize the efficacy of potential bsAb applications. As attention on DL in bsAb development amplifies, these risk factors, along with drug toxicity, can be modeled to improve in the process of drug discovery.

Nevertheless, this technology and similar processes will be revolutionary in the computational field. In the context of precision medicine, it allows for a targeted cancer approach that can be developed faster than traditional solutions or immunotherapies. By doing so, specific receptors that are characteristic of lymphoma subspecies may enhance longevity and mitigate the impact of the disease.

5. CONCLUSION

Out of the fixed antibody set, a bispecific antibody composed of the 1A5F and 1IQW Fab fragments would be the most effective in HL and ALCL treatment targeting the CD30 and CD3ε receptors. Using DL and computational software to accelerate bsAb development can enhance the popularity and use of these applications, even contributing to more efficient high-throughput technologies and systems. The elementary methods discussed in this research can be effective when paired with systems used to reduce toxicity and, more accurately, model response prediction, increasing relevance in contemporary laboratories and pharma organizations.

6. REFERENCES

(1) Siegel, L. R.; Giaquinto, N. A.; Jemal, A. Cancer statistics, 2024. CA: A Cancer Journal for Clinicians 2024, 74 (1), 12-49. DOI: 10.3322/caac.21820.

(2) Vose, J. M.; Bierman, P. J.; Armitage, J. O.; Goldman, J. M. Diagnosis and treatment of non-Hodgkin's lymphoma of adults. In Neoplastic Diseases of the Blood, 5 ed.; Wiernik, P. H., Goldman, J. M., Dutcher, J. P., Kyle, R. A. Eds.; Springer, 2013; pp 1027-1047.

(3) Gustavsson, A.; Osterman, B.; Cavallin-Ståhl, E. A Systematic Overview of Radiation Therapy Effects in Non-Hodgkin's Lymphoma. Acta Oncologica 2003, 42 (5-6), 605-619. DOI: 10.1080/02841860310014435.

(4) Zappasodi, R.; Braud, D. F.; Nicola, D. M. Lymphoma Immunotherapy: Current Status. Frontiers in Immunology 2015, 6. DOI: 10.3389/fimmu.2015.00448.
(5) Howell, D.; Hart, R.; Smith, A.; Macleod, U.; Patmore, R.; Roman, E. 'Unpacking' pathways to lymphoma and myeloma diagnosis: Do experiences align with the Model of Pathways to Treatment? Findings from a UK qualitative study with patients and relatives. BMJ Open 2020. DOI: 10.1136/bmjopen-2019-034244.
(6) Old, L. J. Immunotherapy for Cancer. Scientific American 1996, 275 (3), 136-143. (acccessed 2024/12/02/).JSTOR.
(7) Shiravand, Y.; Khodadadi, F.; Kashani, A. M. S.; Hosseini-Fard, R. S.; Hosseini, S.; Sadeghirad, H.; Ladwa, R.; O'Byrne, K.; Kulasinghe, A. Immune Checkpoint Inhibitors in Cancer Therapy. Current Oncology 2022, 29 (5), 3044-3060. DOI: 10.3390/curroncol29050247.
(8) Kiyotani, K.; Toyoshima, Y.; Nakamura, Y. Personalized immunotherapy in cancer precision medicine. Cancer Biology and Medicine 2021, 18 (-), 0-0. DOI: 10.20892/j.issn.2095-3941.2021.0032.
(9) Madsen, V. A.; Pedersen, E. L.; Kristensen, P.; Goletz, S. Design and engineering of bispecific antibodies: insights and practical considerations. Frontiers in Bioengineering and Biotechnology 2024, 12. DOI: 10.3389/fbioe.2024.1352014.
(10) Suurs, V. F.; Hooge, L.-D. N. M.; Vries, D. G. E. E.; Groot, D. A. J. D. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacology & Therapeutics 2019, 201, 103-119. DOI: 10.1016/j.pharmthera.2019.04.006.
(11) Ferrari, M.; Onuoha, C. S.; Fossati-Jimack, L.; Nerviani, A.; Alves, L. P.; Pagani, S.; Deantonio, C.; Colombo, F.; Santoro, C.; Sblattero, D.; et al. Novel Bispecific Antibody for Synovial-Specific Target Delivery of Anti-TNF Therapy in Rheumatoid Arthritis. Frontiers in Immunology 2021, 12. DOI: 10.3389/fimmu.2021.640070.
(12) Menon, P. A.; Moreno, B.; Meraviglia-Crivelli, D.; Nonatelli, F.; Villanueva, H.; Barainka, M.; Zheleva, A.; Santen, V. M. H.; Pastor, F. Modulating T Cell Responses by Targeting CD3. Cancers 2023, 15 (4), 1189. DOI: 10.3390/cancers15041189.
(13) Weyden, D. V. A. C.; Pileri, A. S.; Feldman, L. A.; Whisstock, J.; Prince, M. H. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer Journal 2017, 7 (9), e603-e603. DOI: 10.1038/bcj.2017.85.
(14) Foyil, V. K.; Bartlett, L. N. Anti-CD30 Antibodies for Hodgkin Lymphoma. Current Hematologic Malignancy Reports 2010, 5 (3), 140-147. DOI: 10.1007/s11899-010-0053-y.
(15) Gil, D.; Schamel, W. W. A.; Montoya, M.; Sánchez-Madrid, F.; Alarcón, B. Recruitment of Nck by CD3ϵ Reveals a Ligand-Induced Conformational Change Essential for T Cell Receptor Signaling and Synapse Formation. Cell 2002, 109 (7), 901-912. DOI: 10.1016/S0092-8674(02)00799-7.
(16) Transy, C.; Moingeon, P. E.; Marshall, B.; Stebbins, C.; Reinherz, E. L. Most anti-human CD3 monoclonal antibodies are directed to the CD3ε subunit. European Journal of Immunology 1989, 19 (5), 947-950. DOI: https://doi.org/10.1002/eji.1830190525.
(17) Brinkmann, U.; Kontermann, E. R. The making of bispecific antibodies. mAbs 2017, 9 (2), 182-212. DOI: 10.1080/19420862.2016.1268307.
(18) Ferreira, L.; Santos, D. R.; Oliva, G.; Andricopulo, A. Molecular Docking and Structure-Based Drug Design Strategies. Molecules (Basel, Switzerland) 2015, 20 (7), 13384-13421. DOI: 10.3390/molecules200713384.
(19) Fan, J.; Fu, A.; Zhang, L. Progress in molecular docking. Quantitative Biology 2019, 7 (2), 83-89. DOI: 10.1007/s40484-019-0172-y.
(20) Liu, X.; Zhao, J.; Guo, X.; Song, Y. CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting. Journal of Hematology & Oncology 2023, 16 (1). DOI: 10.1186/s13045-023-01488-4.
(21) Faber, L. M.; Oldham, A. A. R.; Thakur, A.; Rademacher, J. M.; Kubicka, E.; Dlugi, A. T.; Gifford, A. S.; Mckillop, M. W.; Schloemer, J. N.; Lum, G. L.; et al. Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity. Frontiers in Immunology 2023, 14. DOI: 10.3389/fimmu.2023.1225610.
(22) Bateman, A.; Martin, M.-J.; Orchard, S.; Magrane, M.; Adesina, A.; Ahmad, S.; Bowler-Barnett, H. E.; Bye-A-Jee, H.; Carpentier, D.; Denny, P.; et al. UniProt: the Universal Protein Knowledgebase in 2025. Nucleic Acids Research 2024. DOI: 10.1093/nar/gkae1010.
(23) Abramson, J.; Adler, J.; Dunger, J.; Evans, R.; Green, T.; Pritzel, A.; Ronneberger, O.; Willmore, L.; Ballard, J. A.; Bambrick, J.; et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 2024, 630 (8016), 493-500. DOI: 10.1038/s41586-024-07487-w.
(24) Meng, C. E.; Goddard, D. T.; Pettersen, F. E.; Couch, S. G.; Pearson, J. Z.; Morris, H. J.; Ferrin, E. T. <scp>UCSF ChimeraX</scp>: Tools for structure building and analysis. Protein Science 2023, 32 (11). DOI: 10.1002/pro.4792.
(25) Tubiana, J.; Schneidman-Duhovny, D.; Wolfson, J. H. ScanNet: an interpretable geometric deep learning model for structure-based protein binding site prediction. Nature Methods 2022, 19 (6), 730-739. DOI: 10.1038/s41592-022-01490-7.
(26) Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Research 2000, 28 (1), 235-242. DOI: https://doi.org/10.1093/nar/28.1.235.
(27) Yan, Y.; Tao, H.; He, J.; Huang, S.-Y. The HDOCK server for integrated protein–protein docking. Nature Protocols 2020, 15 (5), 1829-1852. DOI: 10.1038/s41596-020-0312-x.
(28) Xue, C. L.; Rodrigues, P. J.; Kastritis, L. P.; Bonvin, M. A.; Vangone, A. PRODIGY: a web server for predicting the binding affinity of protein–protein complexes. Bioinformatics 2016, 32 (23), 3676-3678. DOI: 10.1093/bioinformatics/btw514.
(29) Venisetty, R. ligand-receptor-hbond. 2025. https://github.com/Rithvik789/ligand-receptor-hbond (accessed.
(30) Ruffolo, A. J.; Sulam, J.; Gray, J. J. Antibody structure prediction using interpretable deep learning. Patterns 2022, 3 (2), 100406. DOI: 10.1016/j.patter.2021.100406.
(31) Jackman, J.; Chen, Y.; Huang, A.; Moffat, B.; Scheer, M. J.; Leong, R. S.; Lee, P. W.; Zhang, J.; Sharma, N.; Lu, Y.; et al. Development of a Two-part Strategy to Identify a Therapeutic Human Bispecific Antibody That Inhibits IgE Receptor Signaling. Journal of Biological Chemistry 2010, 285 (27), 20850-20859. DOI: 10.1074/jbc.M110.113910.
(32) Segaliny, I. A.; Jayaraman, J.; Chen, X.; Chong, J.; Luxon, R.; Fung, A.; Fu, Q.; Jiang, X.; Rivera, R.; Ma, X.; et al. A high throughput bispecific antibody discovery pipeline. Communications Biology 2023, 6 (1). DOI: 10.1038/s42003-023-04746-w.
(33) Zhang, X.; Wang, H.; Sun, C. BiSpec Pairwise AI: guiding the selection of bispecific antibody target combinations with pairwise learning and GPT augmentation. Journal of Cancer Research and Clinical Oncology 2024, 150 (5). DOI: 10.1007/s00432-024-05740-3.